Overview

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Status:
Completed

Trial end date:
2008-01-01

Target enrollment:

Participant gender:

Summary

The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Molecular NeuroImaging

Collaborator:

Institute for Neurodegenerative Disorders